Optimal duration of oxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer: a meta-analysis
GastroenterologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- International journal of surgery (London, England)
- Publicado em
- 1 mai 2024
- Citações
- 14
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Optimal duration of oxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer: a meta-analysis
Ziyu Kuang, Jiaxi Wang, Kexin Liu, Jingyuan Wu, Jie Li
Descritores MeSH
- Antineoplastic Combined Chemotherapy Protocols
- Colonic Neoplasms
- Neoplasm Staging
- Oxaliplatin
- Risk Factors
- Randomized Controlled Trials as Topic
- Chemotherapy, Adjuvant
- Disease-Free Survival
- Leucovorin
- Fluorouracil
Veja também
Estudos relacionados
- Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial
- Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial
- Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update
- Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer